|
|
|
news/publications
|
News/Publications
Battelle to Perform Verification Studies of IntelligentMDx’s Proprietary Molecular Diagnostic Assay Process Under terms of the agreement Battelle will perform various testing of IntelligentMDx’s Quantitative BK Virus (BKV) Real-Time PCR Assay to identify its performance characteristics. Financial terms of the agreement were not disclosed. BKV has recently emerged as an important pathogen in nephropathy in kidney transplant patients and hemorrhagic cystitis in human stem cell transplant patients. The IntelligentMDx Quantitative BK Virus Real-Time PCR Assay can be utilized to track the course of infection and monitor response to treatment. The biggest hurdle for a nucleic acid testing is that current reagent design methods do not specifically address the core set of challenge affecting reagent performance—such as genetic diversity and other key performance metrics. IntelligentMDx has a proprietary process to manage the design, development and manufacturing of pathogen assays that are platform agnostic and adaptable to all nucleic acid detection methodologies. The IntelligentMDx process allows for rapid time to market. Click here to read the article.
IntelligentMDx CEO Jacobs Chairs Panel at Harvard Business School Alumni Health Industry Conference Jacobs chaired the panel moderated by The Economist’s chief business writer, Mathew Bishop, with other leaders in the world health community: Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases; Stephane Bancel, CEO of BioMeriuex; Sara Sievers, Senior Program Officer for Global Health Advocacy at the Gates Foundation; and Kirk Ririe, Founder of Idaho Technology. The engaging discussion covered a wide variety of issues facing Public Private Partnerships (PPPs), illuminating the need for efficient innovation in dealing with emerging infectious diseases. In speaking of the role that the PPPs can play, Dr. Jacobs stated that they “allow everyone to work on what they’re good at.” She pointed out that because PPPs promote specialization, they can allow for the most effective treatment of mutating pathogens. The discussion also included insights into the evolving role that philanthropic organizations such as the Gates Foundation play in the world of public and private partnerships.
Mass High Tech Features IntelligentMDx in Front-Page Story CAMBRIDGE, MASSACHUSETTS, November 2, 2007 – Today's issue of Mass High Tech highlights IntelligentMDx in a front-page feature story about how IMD can improve the detection of deadly, difficult-to-diagnose superbugs. The reputable journal, which covers the latest developments in New England technology, reports how IMD's tool for designing diagnostics could lead to the first rapid, sensitive and specific test for these antibiotic-resistant Staph. The emergence of superbugs in the national media has propelled IMD into the spotlight with the article calling IMD a life sciences firm "advancing new weapons to do battle against the lethal bacteria." Click here to read the article.
Alice Jacobs, IntelligentMDx’s CEO, Attends the 2007 World Economic Forum in Davos, Switzerland In January 2007, Alice Jacobs, CEO of IntelligentMDx, attended the World Economic Forum (WEF) Annual Meeting in Davos, Switzerland where she participated in policy-advancing health care symposia. The WEF’s Annual Meeting performs a unique role by bringing together world leaders from multiple sectors of society, including political, business, academic, and religious leaders as well as cultural personalities. It provides insight, stimulates an exchange of ideas, provides leaders with opportunities to establish personal connections, and seeks new solutions to the most pressing challenges on the global agenda. Ms. Jacobs also participated in the Forum for Young Global Leaders (YGL) — a separate set of activities sponsored by the World Economic Forum. YGL is a forum for the young, emerging leaders of the next generation to envision the future, initiate global strategies, and develop innovative responses that address some of the world’s most difficult risks and challenges. Ms. Jacobs and the IntelligentMDx team have a deep commitment to the detection and alleviation of infectious diseases and believe IntelligentMDx’s technology can play a significant role in reaching these objectives. At the WEF and YGL conferences, Ms. Jacobs communicated the company’s central message to an international audience: that better diagnostics can produce better therapeutics. For more information on the YGL Programme and the World Economic Forum: www.youngloballeaders.org; www.weforum.org.
Recognized Leaders Join IntelligentMDx’s Boards CAMBRIDGE, MASSACHUSETTS, December 30, 2006 — Intelligent Medical Devices (IntelligentMDx) announced the addition of two highly respected and influential leaders, Fred Frank and Richard Braddock, to its governance team. Fred Frank, Vice Chairman and Director of Lehman Brothers, Inc. has joined the Advisory Board. Mr. Frank is one of the country’s most experienced investment bankers and merger and acquisition advisors in the life sciences industry and a recent recipient of the Albert Einstein Award from the Weizman Institute of Science. His expertise will provide invaluable guidance as IntelligentMDx rolls out its alliance and partnering strategies. Richard Braddock has joined IntelligentMDx's Board of Directors. He is formerly President and COO of Citicorp and most recently Chairman and CEO of priceline.com, Inc. and Chairman-Executive Committee of MidOcean Partners, a private equity firm. Mr. Braddock has deep expertise as both an investor and executive leader in building shareholder value in technology-based businesses.
IntelligentMDx Named to Scientific American 50 CAMBRIDGE, MASSACHUSETTS, November 11, 2004 — Intelligent Medical Devices (IntelligentMDx) has been named to the 2004 Scientific American 50 as Business Leader in Medical Diagnostics, recognizing its outstanding acts of leadership in science and technology. The Scientific American 50 honors the achievements of individuals, organizations and institutions as research, policy and business leaders in science and technology categories ranging from computing and medical treatments to aerospace and energy. It is compiled by the Board of Editors of Scientific American, the nation’s premier magazine devoted to science and technology. |